Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
59,244,054
-
Total 13F shares
-
64,669,430
-
Share change
-
-895,167
-
Total reported value
-
$489,559,204
-
Put/Call ratio
-
115%
-
Price per share
-
$7.57
-
Number of holders
-
145
-
Value change
-
-$25,799,469
-
Number of buys
-
66
-
Number of sells
-
72
Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) as of Q1 2025
As of 31 Mar 2025,
Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) was held by
145 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
64,669,430 shares.
The largest 10 holders included
MPM BIOIMPACT LLC, BVF INC/IL, BlackRock, Inc., DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Lynx1 Capital Management LP, VANGUARD GROUP INC, CITADEL ADVISORS LLC, Blue Owl Capital Holdings LP, Kynam Capital Management, LP, and FRANKLIN RESOURCES INC.
This page lists
145
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.